Skip to main content
SpringerLink
Log in

Isolated Limb Perfusion: What Is the Evidence for Its Use?

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: This study was conducted to assess the best available evidence for the use of isolated limb perfusion.

Methods: Following the principles of Evidence-Based Medicine, we reviewed the best available evidence for isolated limb perfusion (ILP) for melanoma and soft tissue sarcoma (STS) of the limb.

Results: Adjuvant ILP with melphalan (M-ILP) to wide local excision cannot be recommended for patients with primary melanoma with a limited regional benefit and no increase in overall survival (level 1b evidence). Prophylactic M-ILP next to the excision of recurrent melanoma has resulted in a nonsignificant decrease in recurrence rate (33% to 50%), with a significantly longer recurrence-free interval (10 to 17 months), but no survival benefit (level 2b evidence). Therapeutic M-ILP, with or without tumor-necrosis factor alpha and interferon gamma (T(I)M-ILP), seems indicated in unresectable melanoma (level 3 to 4 evidence). In unresectable STS of the limbs, limb salvage can be obtained in 57% to 86% of patients with neoadjuvant T(I)M-ILP (level 3 evidence). A comparison of level 3 to 4 studies on ILP and other neoadjuvant treatment modalities for unresectable STS shows that ILP results in the highest limb salvage rate with the lowest complication rate.

Conclusions: Based on level 3 to 4 evidence, ILP is indicated in unresectable locoregional (recurrent) melanoma and unresectable STS of the limbs. Level 1 and 2b evidence does show an effect of prophylactic ILP on micrometastatic disease in locoregional (recurrent) melanoma of the limb. ILP seems the most effective limb sparing, neoadjuvant treatment modality when compared with other neoadjuvant treatment options for unresectable STS of the limb (level 3 to 4 evidence), although randomized studies are lacking.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based Medicine: How to Practise and Teach EBM Edinburgh: Churchill Livingston: 2000.

    Google Scholar 

  2. Urschel JD, Goldsmith CH, Tandan VR, Miller JD. Users’ guide to evidence-based surgery: how to use an article evaluating surgical interventions. Can J Surg 2001;44:95–100.

    CAS  PubMed  Google Scholar 

  3. Schraffordt Koops H, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998;16:2906–12.

    Google Scholar 

  4. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979;86:343–51.

    CAS  PubMed  Google Scholar 

  5. Fenn NJ, Horgan K, Johnson RC, Hughes LE, Mansel RE. A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb. Eur J Surg Oncol 1997;23:6–9.

    CAS  PubMed  Google Scholar 

  6. Ghussen F, Nagel K, Groth W, Muller JM, Stutzer H. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 1984;200:764–8.

    CAS  PubMed  Google Scholar 

  7. Kroon BBR, Nieweg OE. Management of malignant melanoma. Ann Chir Gynaecol 2000;89:242–50.

    CAS  PubMed  Google Scholar 

  8. Hafstrom L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991;9:2091–4.

    CAS  PubMed  Google Scholar 

  9. Takkenberg RB, et al. Does isolated limb perfusion prolong the limb recurrence-free interval after several episodes of excisional surgery for limb recurrences of melanoma? Ann Surg Oncol, 2003;10–S18

    Google Scholar 

  10. Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996;83:1319–28.

    CAS  PubMed  Google Scholar 

  11. Fraker D, Alexander H, Ross M, et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma. Ann Surg Oncol, 2002;S8.

  12. Kapteijn BA, Klaase JM, van Geel AN, Eggermont AMM, Kroon BBR. Results of regional isolated perfusion for locally inoperable melanoma of the limbs. Melanoma Res 1994;4:135–8.

    CAS  PubMed  Google Scholar 

  13. Liénard D, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491–502.

    Article  PubMed  Google Scholar 

  14. Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996;83:509–12.

    CAS  PubMed  Google Scholar 

  15. Strobbe LJ, Nieweg OE, Kroon BBR. Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. Eur J Surg Oncol 1997;23:435–8.

    CAS  PubMed  Google Scholar 

  16. Overgaard J, Gonzalez GD, Hulshof MC, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995;345:540–3.

    CAS  PubMed  Google Scholar 

  17. Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet 1979;149:17–21.

    CAS  PubMed  Google Scholar 

  18. von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988;61:1071–4.

    CAS  PubMed  Google Scholar 

  19. Strobbe LJ, Hart AA, Rumke P, Israels SP, Nieweg OE, Kroon BB. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 1997;7:507–12.

    CAS  PubMed  Google Scholar 

  20. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479–89.

    CAS  PubMed  Google Scholar 

  21. Rossi CR, Foletto M, Pilati P, Mocellin S, Lise M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2002;29:400–9.

    PubMed  Google Scholar 

  22. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305–15.

    CAS  PubMed  Google Scholar 

  23. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756–64.

    CAS  PubMed  Google Scholar 

  24. Liénard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52–60.

    PubMed  Google Scholar 

  25. Olieman AF, Pras E, van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 1998;40:807–14.

    CAS  PubMed  Google Scholar 

  26. van Etten B, van Geel AN, de Wilt JH, Eggermont AMM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003;10:32–7.

    PubMed  Google Scholar 

  27. Lejeune FJ, Pujol N, Liénard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNF alpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000;26:669–78.

    Article  CAS  PubMed  Google Scholar 

  28. Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997;79:1129–37.

    CAS  PubMed  Google Scholar 

  29. Suit HD, Mankin HJ, Wood WC, et al. Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol 1988;6:854–62.

    CAS  PubMed  Google Scholar 

  30. Tanabe KK, Pollock RE, Ellis LM, Murphy A, Sherman N, Romsdahl MM. Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. Cancer 1994;73:1652–9.

    CAS  PubMed  Google Scholar 

  31. O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359:2235–41.

    Article  PubMed  Google Scholar 

  32. Eilber FR, Guiliano AE, Huth J, Mirra J, Morton DL. High-grade soft-tissue sarcomas of the extremity: UCLA experience with limb salvage. Prog Clin Biol Res 1985;201:59–74.

    CAS  PubMed  Google Scholar 

  33. Huth JF, Eilber FR. Patterns of metastatic spread following resection of extremity soft-tissue sarcomas and strategies for treatment. Seminin Surg Oncol 1988;4:20–6.

    CAS  Google Scholar 

  34. Levine EA, Trippon M, Das Gupta TK. Preoperative multimodality treatment for soft tissue sarcomas. Cancer 1993;71:3685–9.

    CAS  PubMed  Google Scholar 

  35. Temple WJ, Temple CL, Arthur K, Schachar NS, Paterson AH, Crabtree TS. Prospective cohort study of neoadjuvant treatment in conservative surgery of soft tissue sarcomas. Ann Surg Oncol 1997;4:586–90.

    CAS  PubMed  Google Scholar 

  36. Azzarelli A, Quagliuolo V, Fissi S, et al. Intra-arterial induction chemotherapy for soft tissue sarcomas. Ann Oncol, 1992;3(Suppl 2):S67–S70

    PubMed  Google Scholar 

  37. Klaase JM, Kroon BBR, van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994;178:564–72.

    CAS  PubMed  Google Scholar 

  38. Noorda EM, Vrouenraets BC, Nieweg OE, van Coevorden F, van Slooten GW, Kroon BBR. Isolated limb perfusion with TNF-alpha and melphalan for unresectable soft tissue sarcoma of the extremities. Cancer 2003;98:1483–90.

    Article  CAS  PubMed  Google Scholar 

  39. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977;185:555–64.

    CAS  PubMed  Google Scholar 

  40. Lehti PM, Moseley HS, Janoff K, Stevens K, Fletcher WS. Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 1986;162:149–52.

    CAS  PubMed  Google Scholar 

  41. Klaase JM, Kroon BBR, Benckhuijsen C, van Geel AN, Albus-Lutter CE, Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989;64:616–21.

    CAS  PubMed  Google Scholar 

  42. Di Filippo F, Carlini S, Cavalier E, et al. The role of hyperthermic perfusion in the treatment of tumors of the extremities. Adv Exp Med Biol 1990;267:223–34.

    CAS  PubMed  Google Scholar 

  43. Moseley HS. An evaluation of two methods of limb salvage in extremity soft-tissue sarcomas. Arch Surg 1992;127:1169–73.

    CAS  PubMed  Google Scholar 

  44. Rossi CR, Foletto M, Alessio S, et al. Limb-sparing treatment for soft tissue sarcomas: influence of prognostic factors. J Surg Oncol 1996;63:3–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands

    Eva M. Noorda MD, Bart C. Vrouenraets MD, PhD, Omgo E. Nieweg MD, PhD, Frits van Coevorden MD, PhD & Bin B. R. Kroon MD, PhD

  2. The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX Amsterdam, the Netherlands

    Eva M. Noorda MD

Authors
  1. Eva M. Noorda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bart C. Vrouenraets MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omgo E. Nieweg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frits van Coevorden MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bin B. R. Kroon MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eva M. Noorda MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Noorda, E.M., Vrouenraets, B.C., Nieweg, O.E. et al. Isolated Limb Perfusion: What Is the Evidence for Its Use?. Ann Surg Oncol 11, 837–845 (2004). https://doi.org/10.1245/ASO.2004.12.042

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2004.12.042

Key Words

Search

Navigation